By the beginning of 1990, Amgen - the pharmaceutical company began a little over a decade ago, as applied molecular genetics - was within reach of becoming a billion dollars. With two highly successful biotechnology drugs on the market, Amgen stood as the largest and most powerful independent company of its kind in the world. Top managers in the company of long-term planning is considered as an important ingredient in the success of the company, and many others - including some scientists firms - were less confident. Amgen's sales volume is expected to continue to grow rapidly, long-term planning process of the company will be put to the test. Shows the different, sometimes paradoxical perspectives held within one of the company's dynamic to the issue of long-term planning. Students are challenged to synthesize these views into a coherent picture of the company's growth amid great uncertainty. "Hide
by Nitin Nohria, James D. Berkley Source: Harvard Business School 18 pages. Publication Date: March 12, 1992. Prod. #: 492052-PDF-ENG
Related Case Solutions & Analyses:
This Case Sucks: Beavis Butt-head and TV Content (A)
Horizon Group
CompuServe (C)
Dakota Office Products
Extending the ‘easy’ business model
Sophis Networks and Encryption Export Controls (A)
Blue River Technology A
Rina Castillo Implementing Asset Allocation Principles
Nike Sustainability and Labor Practices 2008-2013
Uber 21st Century Technology Confronts 20th Century Regulation
